Patients must have lactate dehydrogenase (LDH) obtained within  days prior to registration in order to obtain baseline stratification information

Serum lactate dehydrogenase (LDH) <  X ULN (patients with LDH >  X ULN are felt to have aggressive disease and should be considered for BRAF inhibitor therapy off protocol), obtained within  weeks prior to randomization

Patients must have the following components of Follicular Lymphoma International Prognostic Index (FLIPI) available from diagnosis, and collected again at time of registration:\r\n* Age\r\n* Lactate dehydrogenase (LDH)\r\n* Number of nodal groups involved\r\n* Serum or plasma hemoglobin \r\n* Ann Arbor stage\r\nAdditionally, patients must have beta--microglobulin collected at time of registration

Patients must have lactate dehydrogenase (LDH) performed within  days prior to registration

Within  (except as noted) days of planned treatment initiation: Lactate dehydrogenase (LDH) =< . x institutional ULN (may be within  days)

Baseline labs as within standard of care (complete blood count [CBC], comprehensive metabolic panel [CMP], lactate dehydrogenase [LDH], erythrocyte sedimentation rate [ESR], etc) are required within  days of enrollment

Lactate dehydrogenase (LDH) =< . x ULN

Patients with symptomatic leukemic meningitis, bony or gastrointestinal (GI) tract involvement, serum calcium or lactate dehydrogenase (LDH) > . X the upper limit of normal will be excluded; however, patients that have both ATL and another HTLV- associated disease such as tropical spastic paraparesis (HTLV-I-associated myelopathy [HAM]/tropical spastic paraparesis [TSP]) will be included

Subjects must have serum lactate dehydrogenase (LDH) > institutional upper limit of normal (ULN) at time of study enrollment

LDH <  times ULN for each institution.

Serum lactate dehydrogenase (LDH) level =< . upper limit of normal (ULN) within  days prior to enrollment

Serum lactate dehydrogenase (LDH) levels < .  ULN

LDH ?. times the ULN.

Serum lactate dehydrogenase (LDH) not greater than . times the upper limit of the local laboratory assay within  days of RPLND

LDH <  x ULN

Normal serum lactate dehydrogenase (LDH)

Lactate dehydrogenase (LDH) - no clinically significant findings

Serum lactate dehydrogenase (LDH) > . x institutional ULN

At least one risk factor predicting higher likelihood of bone marrow sample yield: elevated alkaline phosphatase, low hemoglobin, or elevated lactate dehydrogenase (LDH)

Melanoma patients with an LDH ?  x ULN.

Serum lactate dehydrogenase (LDH) =<  X ULN

Lactate dehydrogenase (LDH) <   upper limits of normal\r\n* (NOTE: these criteria will select against patients with bulky disease and will select for patients with less disease and earlier disease)

Patient with group classification A disease, or group classification B stage I or II disease with normal lactate dehydrogenase (LDH) level AND tumor mass less than  cm; NOTE: Patients who would be excluded from treatment on this protocol strictly for laboratory or performance status abnormalities can be included at the principal investigators discretion after consultation with the members of the Texas Children's Hospital (TXCH) Lymphoma Team

Current or prior features of acute (corrected calcium [Ca]++ > . or lactate dehydrogenase [LDH] > -fold above ULN) or chronic (LDH .--fold above ULN or absolute lymphocyte count >  x ^/L with T-cells > . x ^/L) ATL; patients with smoldering ATL (no acute or chronic features) and symptomatic ATL skin lesions are also eligible

The following tests must be performed within  days prior to registration either for diagnosis/staging or to obtain baseline values:\r\n* White blood cells (WBC)\r\n* Hemoglobin\r\n* Lactate dehydrogenase (LDH)\r\n* Hepatitis B-surface antigen (Ag) and anti-core antibody (Ab)

Patients must have lactate dehydrogenase (LDH) performed within  days prior to registration

Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of  or  and must have a serum lactate dehydrogenase (LDH) ? . X upper limit of normal and adequate hematologic, hepatic, renal, and coagulation organ function- Other criteria may apply

LDH level ? .  ULN at screening

LDH level ? .  ULN at screening.

Within  weeks of administration of study therapy: Lactate dehydrogenase (LDH) <  x upper limit of normal (ULN)

Patients with melanoma must have a serum lactate dehydrogenase (LDH) test performed within  days prior to registration

Stage III with elevated LDH level (\B-high\), [LDH > twice the institutional upper limit of the adult normal values (> Nx)] or any stage IV or B-AL.

Meets criteria for poor-risk defined as  or more of the following: ECOG performance status , anemia (hemoglobin lower than reference range), elevated serum lactate dehydrogenase (LDH) > . x upper limit of normal (ULN), hypercalcemia (corrected serum calcium level > upper limit of normal), time from initial RCC diagnosis to registration on this trial <  year, and >  metastatic organ sites

Gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and alkaline phosphatase =< . x institutional ULN

Lactate dehydrogenase (LDH) within normal limits (WNL)

Elevated lactate dehydrogenase (any elevation above normal range)

Sufficient data to calculate the International Prognostic Index (IPI) score at baseline:\r\n* Age\r\n* Stage of disease\r\n* Lactate dehydrogenase (LDH)\r\n* ECOG performance status\r\n* Number of extranodal sites

increase in serum Lactase Dehydrogenase (LDH)

Subject has a known elevation in serum lactate at screening ? x institutional ULN

Lactate dehydrogenase (LDH) ?  times the upper limit of normal (ULN).

Lactate dehydrogenase (LDH): there is no restriction

Patients must have lactate dehydrogenase (LDH) obtained prior to registration

Lactate dehydrogenase <  x ULN

Lactate dehydrogenase (LDH) less than . times below or above the upper or lower limit range

Lactate dehydrogenase (LDH) less than . times below or above the upper or lower limit range

LDH ?. times the ULN range of each institution